Targeting PIK3CA signaling to treat pancreatic cancer
Official title: PIK3CA signaling and pancreatic cancer
Funded at State University New York Stony Brook · NIH-10884910 · Data updated 2026-11-12
This study is looking at how to better target a specific pathway in pancreatic cancer to help improve treatment options, especially for patients who may not be responding well to current therapies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | July 8, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $174,108 |
| NIH project number | 5R21CA274425-02 |
| Project ID | NIH-10884910 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
✕Less likely to help
Patients with other types of cancer or those without KRAS mutations may not benefit from this research.
What this research studies
This research investigates how to effectively target PIK3CA signaling pathways to improve treatment outcomes for pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer. The study aims to understand the role of PIK3CA in tumor growth and immune evasion, utilizing animal models to explore genetic modifications and drug interventions. By examining how PIK3CA interacts with oncogenic KRAS mutations, the research seeks to identify new therapeutic strategies that could enhance the effectiveness of existing treatments, including immunotherapy. Patients may benefit from insights gained into how to overcome resistance to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Lin, Richard Z — State University New York Stony Brook
- Study coordinator: Lin, Richard Z
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.